Cue Biopharma, Inc.

CUENASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
31.64 USD
↗ 1.09 (3.57%)AT CLOSE (11:59 AM EDT)
31.20
↘ 0.44 (1.38%)
POST MARKET (AS OF 07:53 PM EDT)
Post Market
AS OF 07:53 PM EDT
31.20
↘ 0.44 (1.38%)
🔴Market: CLOSED

CUE is currently priced at $31.66. CUE shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, CUE trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Sep 15, 2026.

Open?$30.65
High?$32.00
Low?$29.26
Prev. Close?$30.55
Volume?127.2K
Avg. Volume?177.1K
VWAP?$30.81
Rel. Volume?0.72x
Bid / Ask
Bid?$29.80 × 300
Ask?$31.40 × 400
Spread?$1.60
Midpoint?$30.60
Valuation & Ratios
Market Cap?221.9M
Shares Out?7.3M
Float?3.5M
Float %?87.6%
P/E Ratio?N/A
P/B Ratio?96.07
EPS?-$22.59
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
29
Market Cap
221.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.cuebiopharma.com
Listed
2018-01-02
Address
40 GUEST STREET
BOSTON, MA 02135
Phone: 617-949-2680
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
23
Short Sent.?
66
Piotroski F-Score?2/9Weak
Altman Z-Score?-28.49Distress
Confidence?51%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?8.98%Elevated
Short Interest?318.4K
Days to Cover?1.8
Free Float3.5M
Avg Daily Volume180.7K
Settlement Date2026-08-31
Financial Health
Current Ratio?1.25Adequate
Quick Ratio?1.25Adequate
Cash Ratio?0.82Adequate
Debt/Equity?0.42Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
96.07HIGH▾
P/S?
Peers
100
S&P
23
5.89FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.1CHEAP▾
EV/Sales?
Peers
100
S&P
32
5.46FAIR▾
Returns & Efficiency
ROE?
S&P
3
-7,104.2%WEAK▾
ROA?
S&P
3
-534.4%WEAK▾
Cash Flow & Enterprise
FCF?$-50167000
Enterprise Value?$205.5M
Fundamentals ratios updated end of day
MarketsMoversWatchlist